33 results about "Antithrombins" patented technology

The invention discloses a group of pyemia specific biomarkers and application thereof, and belongs to the field of medical detection.The biomarkers are formed by combination of alpha 1-microglobulin / Bikunin precursor protein and one or more of antithrombin III protein, apolipoprotein A1 or apolipoprotein H, according to the invention, seven core proteins, namely APOA1, APOH, AMBP, SERPINC1, F2, FGG and FGB, are screened from TMT proteomics of serum of a clinical hemorrhagic patient, and four more important proteins, namely APOA1, APOH, AMBP, SERPINC1, F2, FGG and FGB, are obtained by further screening the seven proteins in a hemorrhagic cell model and the clinical hemorrhagic patient. The four proteins are verified again in serum of a hemorrhagic mouse animal experiment and an expanded-scale clinical hemorrhagic patient, and the potential of the four core proteins as serum biomarkers for early diagnosis of hemorrhagic disease is determined.

The present invention relates to the use of Antithrombin in the treatment of stroke.

The application discloses a method for preparing and removing odor of Hirudo nipponia freeze-dried powder, and the method comprises the following steps: inducing clean treatment in an empty stomach, low-temperature stress pretreatment, in-situ quick freezing under the protection of inert gas, segmented vacuum freeze-drying and low-temperature airflow crushing. The application induces the expression up-regulation of aldehyde dehydrogenase and alcohol dehydrogenase in the body of Hirudo nipponia through low-temperature stress, and utilizes ice crystals to destroy cell compartmentalization in in-situ quick freezing, so that the enzymes and their substrates are contacted, in-situ enzymatic conversion occurs under the protection of inert gas, and fishy components are degraded into low-smell metabolites. The application does not need exogenous odor-removing substances and post-processing procedures, has high antithrombin activity retention rate, greatly reduces the total amount of fishy substances, and realizes in-situ synergistic odor removal in the whole freeze-drying process.

The present application relates to the technical field of biological medicine, and provides a thrombin-antithrombin III complex antibody, a detection kit and application thereof.The present application specifically discloses a thrombin monoclonal antibody and an antithrombin III monoclonal antibody pairing combination, an intermediate product and a detection kit product containing the same.The antibody combination of the present application can be combined with the thrombin-antithrombin III complex in a double-antibody sandwich method with high sensitivity and strong specificity;the thrombin-antithrombin III complex detection kit suitable for the immunochemiluminescence method is prepared by using the above antibody, and the thrombin-antithrombin III complex in the human body can be detected by a two-step method.

This invention relates to the field of antibodies, and more particularly to TAT antibodies and their applications. The invention provides coated antibodies comprising a heavy chain variable region and a light chain variable region, wherein: the CDR1, CDR2, and CDR3 regions of the heavy chain variable region have amino acid sequences as shown in SEQ ID No:1 to SEQ ID No:3; and the CDR1, CDR2, and CDR3 regions of the light chain variable region have amino acid sequences as shown in SEQ ID No:4 to SEQ ID No:6. This invention successfully prepared highly specific monoclonal antibodies 7E10 and 2B4 against the thrombin-antithrombin III complex (TAT), wherein 7E10 specifically binds to thrombin (THR), and 2B4 specifically binds to antithrombin III (AT-III). Using these two antibodies in combination enables highly sensitive and specific detection of the TAT complex.

There has been demand for a pharmaceutical composition containing blood coagulation factor X in which the amount of FXa is suppressed. Provided is a pharmaceutical composition containing blood coagulation factor X, the pharmaceutical composition furthermore containing antithrombin III.

The invention pertains to a therapeutic formulation, CARDIOGARDIA, for the management of cardiac arrest. The formulation co-formulates selected microRNAs, including miR-21, miR-1, miR-29, miR-17, and miR-133, and antithrombin and essential electrolytes in a single formulation. The different components in combination target various pathological processes associated with cardiac arrest, including fibrosis, apoptosis, arrhythmia, and coagulopathy. Delivery may be affected by suitable pharmaceutical vehicles or carriers to enable effective delivery. By acting on these distinct pathological processes in combination, the formulation provides a multifaceted approach to stabilizing cardiac function and improving resuscitation outcome. The invention further encompasses methods of treating subjects experiencing cardiac arrest by administering the formulation in therapeutically effective amounts.

Various embodiments of the invention utilize chalcones to treat blood, bleeding, and / or bleeding disorders. As described herein, chalcones significantly reduce blood clotting time in normal / hemophilic blood and normal / hemophilic animal models. As also described herein, chalcones reduce blood clotting time and increase blood clotting efficiency without any apparent risk of immunogenicity or unwanted blood clots. As also described herein, chalcones reduce the inhibitory activity of antithrombin on thrombin-driven blood clotting, thereby increasing the effectiveness of the thrombin mechanism in clotting blood.

The invention provides a method for improving the appearance of a freeze-dried antithrombin III product. The method comprises the following steps: carrying out pre-freezing treatment and sublimation drying treatment on a sample containing antithrombin III; the pre-freezing treatment comprises at least two cooling steps, and the temperature of each cooling step is-60 to-20 DEG C independently; the sublimation drying treatment comprises at least three heating steps, and the temperature of each heating step is-45 DEG C to 0 DEG C independently. The antithrombin III freeze-dried product obtained by the method disclosed by the invention meets the requirements of pharmacopoeia quality standards, and has the advantages of good molding, full appearance, no shrinkage, no collapse, no compact film layer at the top, high mechanical strength, good product stability and high market value, and is beneficial to storage and transportation.

The invention relates to the technical field of biological medicine, and provides a thrombin-antithrombin III compound antibody, a detection kit and application of the thrombin-antithrombin III compound antibody. The invention specifically discloses a pairing combination of a thrombin monoclonal antibody and an antithrombin III monoclonal antibody, an intermediate product, a detection reagent product containing the pairing combination and the intermediate product, and the like. The antibody combination disclosed by the invention can be combined with a thrombin-antithrombin III compound with high sensitivity and strong specificity by a double-antibody sandwich method; a thrombin-antithrombin III compound detection kit suitable for an immunochemiluminescence method is prepared by using the antibody, and the thrombin-antithrombin III compound in a human body can be detected by a two-step method.

The application relates to the technical field of biological medicine, and particularly discloses a kit for determining antithrombin III activity, which comprises a first reagent, a second reagent, a third reagent and a diluent; the first reagent at least comprises a first buffer, thrombin, a serine protease inhibitor and a first stabilizer; the second reagent at least comprises a second buffer, a chromogenic substrate and a second stabilizer; the third reagent at least comprises a third buffer, heparin, isopropyl alcohol and a third stabilizer; and the diluent at least comprises physiological saline and a fourth stabilizer. In the kit, the cost is low, the anti-interference capability is strong, the sensitivity is high, the stability is good, and the kit has a wide application prospect.

Various embodiments of the invention utilize flavanones, including, but not limited to, 3-hydroxyflavone compounds and 3-hydroxyflavone sugar compounds, to treat blood, bleeding, and / or bleeding disorders. As described herein, flavanones significantly reduce blood clotting time in normal / hemophilic blood and normal / hemophilic animal models. As also described herein, flavanones reduced blood clotting time and increased clotting efficiency in blood without any apparent risk of immunogenicity or risk of unwanted blood clots. As also described herein, flavanones reduce the inhibitory activity of antithrombin on thrombin-driven blood clotting, thereby increasing the effectiveness of the thrombin mechanism in clotting blood.

The application discloses an anti-heparin-antithrombin complex antibody and application thereof in a heparin drug anticoagulation effect detection method, and comprises an antibody molecule capable of combining with a heparin-antithrombin complex, a light chain variable region amino acid sequence of the antibody molecule is shown as SEQ ID NO:1, and a heavy chain variable region amino acid sequence is shown as SEQ ID NO:2. The antibody molecule can be prepared into a kit for detecting the anticoagulation effect of the heparin drug, and has the characteristics of simple operation, high sensitivity, good repeatability, wide linearity and the like, and is suitable for high-throughput testing of the anticoagulation effect of the heparin drug.

The invention relates to an anti-prothrombin / phosphatidylserine antibody, a pharmaceutical composition and an application of the anti-prothrombin / phosphatidylserine antibody. The anti-prothrombin / phosphatidylserine antibody provided by the invention is connected with a prothrombin / phosphatidylserine compound with high affinity, so that the antibody is combined with phosphatidylserine in a targeted manner to achieve the treatment of tumor resistance, infection resistance, thrombosis resistance, atherosclerosis, ischemia-reperfusion injury, inflammatory bowel disease, Alzheimer's disease and Parkinson's disease.

The invention discloses an application of Spy Tag / Spy Catcher in preparation of a thrombin-antithrombin III compound, a preparation method of the thrombin-antithrombin III compound and an application of the thrombin-antithrombin III compound. The preparation method comprises the following steps: respectively obtaining a Spy Catcher-Thrombin gene segment and a Spy Tag-Antithrombin gene segment; respectively connecting the gene segments to starting vectors to form corresponding connectors; carrying out conversion and screening operation on the linker to obtain a corresponding recombinant plasmid; carrying out transformation and induction operation on the recombinant plasmid, so as to obtain a Spy Catcher-Thrombin recombinant protein and a Spy Tag-Antithrombin recombinant protein; the preparation method comprises the following steps: mixing the Spy Catcher-Thrombin recombinant protein with the Spy Tag-Antithrombin recombinant protein, and carrying out a reaction, so as to obtain the TAT protein. According to the method, the spontaneous reaction of Spy Tag / Spy Catcher is utilized, other chemical cross-linking agents are not needed, the cost can be reduced, green production is facilitated, and the recombinant protein can be produced on a large scale by utilizing a cell culture technology; the recombinant TAT antigen and the recombinant TAT antibody prepared by the invention have strong immunoreactivity, and completely meet the requirements of thrombus detection on the TAT antigen.

The present disclosure provides methods and systems for modeling, simulating, and treating hemophilia. The methods and systems disclosed herein include a quantitative systems pharmacology (QSP) model for predicting thrombin generation characteristics in people with hemophilia A and people with hemophilia B in relation to antithrombin (AT) decline.

Compounds and compositions for determining the level of antithrombin (ATIII) in a sample are described. Methods of forming the compounds and compositions are also described. Methods of using the compounds and compositions to quantify the level of ATIII in a subject are further described. The methods can be used to facilitate determining a dosage or heparin or ATIII to administer to a patient.

The invention discloses a traditional Chinese medicine composition for tonifying kidney, nourishing blood and preventing miscarriage as well as a preparation method, a detection method and application thereof, and belongs to the technical field of traditional Chinese medicine, the traditional Chinese medicine composition comprises the following medicine raw materials in parts by weight: 450-550 parts of semen cuscutae, 400-430 parts of Chinese yam, 400-430 parts of angelica sinensis, 400-430 parts of parasitic loranthus, 400-430 parts of teasel root, 400-430 parts of radix paeoniae alba, 400-430 parts of fructus nelumbinis and 230-260 parts of radix aucklandiae. Experimental studies show that the composition can specifically regulate expression levels of thrombosis-related factors (TF, PAI-1 and antithrombin III AT-III) and inflammatory factors (IL-6) in trophoblast cells and vascular endothelial cells, so that placenta local abnormal thrombosis is inhibited, maternal-fetal interface immune inflammation reaction is improved, and recurrent abortion is effectively prevented and treated.

The invention belongs to the technical field of immunodetection analysis, and discloses a kit for quantitative detection of a thrombin-antithrombin III compound and a preparation method of the kit. The kit comprises a magnetic bead working solution, an acridinium ester marker working solution, a biotin marker working solution, a TAT calibrator and a TAT quality control product, and quantitative detection of TAT is realized by combining a double-antibody sandwich method with a chemiluminescence technology. The method overcomes the defects that an existing fluorescence immunoassay method is low in repeatability, and an immunoturbidimetry method is high in requirement for specimens and limited in low-concentration detection capacity, and has the advantages of being high in specificity, sensitivity and accuracy and easy, convenient and rapid to operate. The method can be used for clinical auxiliary diagnosis of thrombogenic diseases such as disseminated intravascular coagulation (DIC) and venous thromboembolism (VTE), and provides a basis for blood coagulation state evaluation and clinical decision making.

The invention relates to the field of biological medicine, in particular to an antithrombin III determination kit and a preparation method thereof. The antithrombin III determination kit comprises a reagent 1, a reagent 2, an ATIII calibration product and an ATIII quality control product. The reagent 1 is prepared from a Tris-HCl buffer solution, calcium chloride, bovine serum albumin, potassium ferrocyanide, gentamicin sulfate, ProClin 300, recombinant human thrombin and a nano blocking agent; the reagent 2 is prepared from a Tris-HCl buffer solution, S-2238, gentamicin sulfate and ProClin 300; the ATIII calibrator is prepared from a synthetic plasma matrix, recombinant human ATIII, natural ATIII, ProClin 300, a blood coagulation inhibitor, protamine and trehalose; the ATIII quality control product is prepared from a synthetic plasma matrix, recombinant human ATIII, natural ATIII, ProClin 300, a blood coagulation inhibitor, trehalose and mannitol, according to the scheme, the method is suitable for a full-automatic blood coagulation analysis platform and conforms to the development trend of in-vitro diagnostic reagents.

Provided in the present invention is an anti-prothrombin / phosphatidylserine antibody, comprising a heavy chain variable region and a light chain variable region; the heavy chain variable region comprises HCDR1 to HCDR3 having amino acid sequences as shown in SEQ ID NOs: 1-3, respectively, and the light chain variable region comprises LCDR1 to LCDR3 having amino acid sequences as shown in SEQ ID NOs: 4-6, respectively. The anti-prothrombin / phosphatidylserine antibody of the present invention can bind to a prothrombin / phosphatidylserine complex with high affinity, thereby targeting and binding to phosphatidylserine, and has a potential therapeutic effect with respect to tumors, infections, atherosclerosis, ischemia-reperfusion injury, inflammatory bowel disease, Alzheimer's disease, Parkinson's disease, etc.

The invention belongs to the technical field of biology, and particularly relates to an anti-human thrombin-antithrombin complex antibody and a preparation method and application thereof and a preparation method of an anti-human thrombin-antithrombin complex (TAT), and the preparation method is characterized by comprising the following steps: (1) expressing and purifying human prothrombin (PT) and human antithrombin III (AT-III); (2) activating PT by using Ecarin snake venom to obtain thrombin (T); and (3) mixing T and AT-III according to a mass ratio of 0.7: 1 for reaction, and purifying to obtain the TAT complex, the invention also comprises a monoclonal antibody secreted by a hybridoma cell strain TAT-2F for specific recognition of TAT and a monoclonal antibody secreted by a hybridoma cell strain T-5B for specific recognition of T and TAT, and the monoclonal antibody provided by the invention can be combined with TAT with high specificity, so that the TAT complex can be used for detecting TAT and TAT. Therefore, the monoclonal antibody can be used for identifying or detecting a patient with abnormal blood coagulation.

The invention provides a method for producing antithrombin III by using a plasma waste component IV precipitate. The method comprises the following steps: dissolving the plasma waste component IV precipitate with a dissolving solution to obtain a component IV dissolving solution; carrying out filter pressing treatment on the component IV dissolving solution, collecting a filter pressing solution, and carrying out ultrafiltration concentration to obtain a chromatography loading solution; performing chromatography purification on the chromatography loading liquid through heparin affinity gel, collecting eluent, and performing ultrafiltration desalination; adding an S / D solution, and carrying out heat preservation and inactivation to obtain a protein solution after S / D; carrying out anion gel chromatography on the protein liquid after S / D to remove the S / D reagent, and eluting to obtain a human antithrombin III stock solution; carrying out ultrafiltration dialysis on the human antithrombin III stock solution, adding alanine and sodium chloride, and pre-filtering to obtain a semi-finished product; and sterilizing, filtering and sub-packaging the semi-finished product, carrying out vacuum freeze drying, and carrying out dry heat virus inactivation treatment to obtain a human antithrombin III finished product. According to the method disclosed by the invention, the plasma waste component IV precipitate is taken as a raw material, and low-cost, high-purity and high-safety production of AT-III is realized by optimizing key steps of dissolution, chromatography, inactivation and the like.

An anticoagulant phenyl-linked heparin oligosaccharide dimer, a preparation method therefor and use thereof are provided. The anticoagulant phenyl-linked heparin oligosaccharide dimer has a structure as represented by general formula I, and the phenyl may be replaced with substituted phenyl, heteroaryl or substituted heteroaryl. The described phenyl-linked heparin oligosaccharide dimer may be synthesized in fewer steps, has a significantly higher total yield, potent and specific antithrombin-dependent anti-Factor Xa activity without significant anti-FactorIIa activity, the anticoagulant activity may be efficiently neutralized by protamine sulfate, has excellent pharmacokinetic profiles, making it suitable for the preparation of novel anticoagulant and antithrombotic drugs that are cost-effective, higher-quality and safer.

This invention discloses the application of sodium thiocyanate in the preparation of a kit for coagulation assays. The kit detects coagulation parameters based on coagulation methods, chromogenic substrate methods, or immunoturbidimetric assays. These coagulation parameters include prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen, fibrin(ogen) degradation products, D-dimer, antithrombin III, and anti-Xa. By adding sodium thiocyanate to the coagulation assay kit, this invention optimizes the clinical relevance of the assay kit by adjusting reaction time (coagulation method), improving the linear range (chromogenic substrate method), and enhancing the differentiation between low and high values ​​(immunoturbidimetric assay), thereby improving the accuracy of the test.

The application discloses a set of sepsis-specific biomarkers and application thereof, and belongs to the medical detection field.The marker is composed of the combination of alpha 1-microglobulin / Bikunin precursor protein and one or more of antithrombin III protein, apolipoprotein A1 or apolipoprotein H.Through TMT proteomics screening of serum of clinical sepsis patients, seven core proteins, APOA1, APOH, AMBP, SERPINC1, F2, FGG and FGB, are screened out.Further screening of the seven proteins in a sepsis cell model and clinical sepsis patients obtains four more important proteins, APOA1, APOH, AMBP and SERPINC1.The four proteins are verified again in a sepsis mouse animal experiment and serum of clinical sepsis patients on a large scale, and the potential of the four core proteins as serum biomarkers for early diagnosis of sepsis is determined.

A protease-resistant ADAMTS13 mutant protein or nucleic acid encoding the ADAMTS13 mutant protein is provided. The ADAMTS13 mutant protein comprises a mammalian ADAMTS13 protein in which one or more protease cleavage sites within the protein are replaced with amino acid sequence that is resistant to protease cleavage, and the mutant protein retains von Willebrand factor (VWF)-cleaving activity. The protease-resistant ADAMTS13 mutant is useful as a thrombolytic agent to treat common thrombotic disorders, including stroke, myocardial infarction, venous thromboembolism, and rare microvascular thrombotic disorders like thrombotic thrombocytopenia purpura (TTP).

This invention discloses an antithrombin III activity detection reagent, comprising a heparin diluent, a thrombin reagent, and a chromogenic substrate reagent. The heparin diluent includes heparin, a first buffer solution, EDTA, sodium chloride, and a preservative. The thrombin reagent includes thrombin, a second buffer solution, a protective agent, an inorganic salt, and a preservative. The chromogenic substrate reagent includes a chromogenic substrate and a preservative. This invention uses a chromogenic substrate method, which offers high sensitivity and accuracy, improves the stability of the thrombin reagent, and ensures the reagent's safety and stability, while also demonstrating good synergistic effects among its components.

Compounds and compositions for determining the level of antithrombin (ATIII) in a sample are described along with a system for determining the level of ATIII in a point-of-care setting. Methods of forming the compounds and compositions are also described. Methods of using the compounds and compositions to quantify the level of ATIII in a subject are further described. A system and apparatus are provided that determine the level of ATIII in a point-of-care setting in an efficient manner to facilitate determining a dosage or heparin or ATIII to administer to a patient.